The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Open accessAbstract
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. METHODS: We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes. RESULTS: Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06). CONCLUSIONS: Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although our analysis is secondary, reanalyses of clinical trial data have led to the detection of adverse events well after the market entry of major drugs such as rofecoxib and rosiglitazone. [36,37]”
From Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults (2022) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In one study, 9 the use of rosiglitazone decreased the risk of diabetes in adults with impaired glucose tolerance by 62%; given concerns about cardiovascular safety, 14 however, the Food and Drug Administration has restricted the use of rosig litazone therapy to patients in whom glycemic control cannot be achieved with other medications and who cannot take pioglitazone.”
From Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“a well-publicized meta-analysis of small phase 3 trials suggesting an increase in myocardial ischemic events (odds ratio, 1.43 [95% CI, 1.03–1.98])”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [210]
In the citing paper
“Several meta-analyses have suggested a 30–40% relative increase in risk for myocardial infarction (65,66) with rosiglitazone.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 552
Self-citationEffect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus
Fonseca, V. A., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 538
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jc.86.1.280 · DOI
Cited by
Sorted by citations
Items 301–400 of 1,024
Interactions between kidney disease and diabetes: dangerous liaisons
Pecoits‐Filho, R., Abensur, H., Betônico, C. D. C. R., Machado, A. D., Parente, E. B., Queiroz, M. S., Salles, J. E. N., Titan, S., & Vencio, S. A. C. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0159-z · Cited by 180
Metabolic Syndrome: From Global Epidemiology to Individualized Medicine
Batsis, J. A., Nieto-Martínez, R. E., & López-Jiménez, F. A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100355 · Cited by 171
Juurlink, D. N., Gomes, T., Lipscombe, L. L., Austin, P. C., Hux, J. E., & Mamdani, M. (2009) · BMJ · doi:10.1136/bmj.b2942 · Cited by 170
Nathan, D. M. (2009) · Diabetes Care · doi:10.2337/dc08-2195 · Cited by 170
Marzio, D. D. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s993 · Cited by 169
Molecular recognition of nitrated fatty acids by PPARγ
Li, Y., Zhang, J., Schopfer, F. J., Martynowski, D., Garcia-Barrio, M. T., Kovach, A., Suino-Powell, K., Baker, P. R. S., Freeman, B. A., Chen, Y. E., et al. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1447 · Cited by 168
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s61438 · Cited by 171
Tan, C. Y., & Vidal‐Puig, A. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360935 · Cited by 169
Thiazolidinediones: effects on insulin resistance and the cardiovascular system
QUINN, C. E., Hamilton, P., Lockhart, C., & McVeigh, G. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707452 · Cited by 168
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B. M., Ghosh, S. K., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 182
Interference with PPARγ Function in Smooth Muscle Causes Vascular Dysfunction and Hypertension
Halabi, C. M., Beyer, A., de Lange, W. J., Keen, H. L., Baumbach, G. L., Faraci, F. M., & Sigmund, C. D. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.008 · Cited by 166
The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience
Doshi, P., Jefferson, T., & Mar, C. D. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001201 · Cited by 166
AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease
Wong, A., Howie, J., Petrie, J. R., & Lang, C. C. (2009) · Clinical Science · doi:10.1042/cs20080066 · Cited by 170
Advances in the Treatment of Type 2 Diabetes Mellitus
Israili, Z. H. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 163
Insulin Resistance in Patients with Chronic Kidney Disease
Liao, M.-T., Sung, C., Hung, K.-C., Wu, C., Lo, L., & Lu, K. (2012) · BioMed Research International · doi:10.1155/2012/691369 · Cited by 180
Malapaka, R. R. V., Khoo, S. K., Zhang, J., Choi, J. H., Zhou, X. E., Xu, Y., Gong, Y., Li, J., Yong, E., Chalmers, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.294785 · Cited by 169
Sturek, J. M., Castle, J. D., Trace, A. P., PAGE, L. C., Castle, A. M., Evans‐Molina, C., Parks, J. S., Mirmira, R. G., & Hedrick, C. C. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41280 · Cited by 163
Schweizer, A., Dejager, S., Foley, J. E., Couturier, A., Ligueros‐Saylan, M., & Kothny, W. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01215.x · Cited by 162
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Mahaffey, K. W., Hafley, G. E., Dickerson, S., Burns, S., Tourt-Uhlig, S., White, J. A., Newby, L. K., Michel Komajda, N., McMurray, J. J. V., Bigelow, R., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.004 · Cited by 165
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
The PPAR-RXR Transcriptional Complex in the Vasculature
Plutzky, J. (2011) · Circulation Research · doi:10.1161/circresaha.110.226860 · Cited by 161
Hauber, B., Mohamed, A. F., Johnson, F. R., & Falvey, H. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02696.x · Cited by 161
Hypoglycemia, Diabetes, and Cardiovascular Disease
Snell‐Bergeon, J. K., & Wadwa, R. P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0031 · Cited by 167
Diabetes and inflammation: Fundamental aspects and clinical implications
Garcia, C., Fève, B., Ferré, P., Halimi, S., Baïzri, H., Bordier, L., Guiu, G., Dupuy, O., Bauduceau, B., & Mayaudon, H. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.07.001 · Cited by 167
Patil, H., Badarin, F. J. A., Shami, H. A. A., Bhatti, S. K., Lavie, C. J., Bell, D. S. H., & O’Keefe, J. H. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.061 · Cited by 161
The nuclear receptor PPARγ individually responds to serotonin‐ and fatty acid‐metabolites
Waku, T., Shiraki, T., Oyama, T., Maebara, K., Nakamori, R., & Morikawa, K. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.197 · Cited by 161
Shabalala, S. C., Dludla, P. V., Mabasa, L., Kappo, A. P., Basson, A. K., Pheiffer, C., & Johnson, R. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110785 · Cited by 169
Cholesterol in islet dysfunction and type 2 diabetes
Brunham, L. R., Kruit, J. K., Verchere, C. B., & Hayden, M. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33296 · Cited by 158
Ciani, O., Buyse, M. E., Drummond, M., Rasi, G., Saad, E. D., & Taylor, R. S. (2016) · Value in Health · doi:10.1016/j.jval.2016.10.011 · Cited by 158
Asghar, O., Alsunni, A. A., Khavandi, K., Khavandi, A., Withers, S., Greenstein, A. S., Heagerty, A. M., & Malik, R. A. (2009) · Clinical Science · doi:10.1042/cs20080500 · Cited by 162
Yassa, H. D., & Tohamy, A. F. (2014) · Acta Histochemica · doi:10.1016/j.acthis.2014.02.002 · Cited by 157
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Fei, Y., Tsoi, M. F., & Cheung, B. M. Y. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0916-z · Cited by 159
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
Updates on the Management of Diabetes in Dialysis Patients
Rhee, C. M., Leung, A. M., Kovesdy, C. P., Lynch, K. E., Brent, G. A., & Kalantar‐Zadeh, K. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12198 · Cited by 158
Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
Phung, O. J., Schwartzman, E., Allen, R. W., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetic Medicine · doi:10.1111/dme.12232 · Cited by 153
Diabetes drugs and neurological disorders: new views and therapeutic possibilities
Patrone, C., Eriksson, O., & Lindholm, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70125-6 · Cited by 151
PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Ahmed, W., Ziouzenkova, O., Brown, J. D., Devchand, P. R., Francis, S. A., Kadakia, M., Kanda, T., Orasanu, G., Sharlach, M., Zandbergen, F. J., et al. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01825.x · Cited by 153
Wang, Z., Yao, T., Pini, M., Zhou, Z., Fantuzzi, G., & Song, Z. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00249.2009 · Cited by 153
Ratner, R. E., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. Z. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 153
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
CNODES: the Canadian Network for Observational Drug Effect Studies.
Suissa, S., Henry, D. A., Caetano, P. A., Dormuth, C. R., Ernst, P., Hemmelgarn, B. R., LeLorier, J., Levy, A. R., Martens, P. J., Paterson, J. M., et al. (2012) · Europe PMC (PubMed Central) · Cited by 153
Ye, Y., Keyes, K. T., Zhang, C., Perez-Polo, J. R., Lin, Y., & Birnbaum, Y. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00867.2009 · Cited by 152
Anti-angiogenic treatment strategies for the therapy of endometriosis
Laschke, M. W., & Menger, M. D. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms026 · Cited by 153
Campbell, R. K. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09077 · Cited by 152
Autophagy: controlling cell fate in rheumatic diseases
Rockel, J. S., & Kapoor, M. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.92 · Cited by 151
Hopper, I., Billah, B., Skiba, M., & Krum, H. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711421687 · Cited by 149
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
Lee, M., Saver, J. L., Liao, H.-W., Lin, C.-H., & Ovbiagele, B. (2017) · Stroke · doi:10.1161/strokeaha.116.013977 · Cited by 147
Desai, N. R., Shrank, W. H., Fischer, M. A., Avorn, J., Liberman, J. N., Schneeweiß, S., Pakes, J., Brennan, T. A., & Choudhry, N. K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.07.033 · Cited by 151
Hennekens, C. H. (2009) · JAMA · doi:10.1001/jama.2009.1756 · Cited by 149
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy, D. J., & Yellon, D. M. (2008) · Heart · doi:10.1136/hrt.2007.125401 · Cited by 151
Pomegranate: a fruit that ameliorates metabolic syndrome
Medjakovic, S., & Jungbauer, A. (2012) · Food & Function · doi:10.1039/c2fo30034f · Cited by 148
Evans‐Molina, C., Robbins, R. D., Kono, T., Tersey, S. A., Vestermark, G. L., Nunemaker, C. S., Garmey, J. C., Deering, T. G., Keller, S. R., Maier, B., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01179-08 · Cited by 147
Teodoro, J. S., Nunes, S., Rolo, A. P., Reis, F., & Palmeira, C. M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01857 · Cited by 150
The effect of glucagon-like peptide 1 on cardiovascular risk
Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 147
Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01154.x · Cited by 144
Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies
Ferwana, M. S., Firwana, B., Hasan, R., Al-Mallah, M. H., Kim, S., Montori, V. M., & Murad, M. H. (2013) · Diabetic Medicine · doi:10.1111/dme.12144 · Cited by 146
A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice
Roessger, K., Hamri, G. C., & Fussenegger, M. (2013) · Nature Communications · doi:10.1038/ncomms3825 · Cited by 146
Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration
Woodcock, J., Sharfstein, J. M., & Hamburg, M. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1010788 · Cited by 146
Yang, D., Yang, H., Li, W., Zhao, B., Ouyang, Z., Liu, Z., Zhao, Y., Fan, N., Song, J. W., Tian, J., et al. (2011) · Cell Research · doi:10.1038/cr.2011.70 · Cited by 146
Targeting mitochondrial oxidative metabolism as an approach to treat heart failure
Fillmore, N., & Lopaschuk, G. D. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.08.014 · Cited by 146
Role of Lipotoxicity in Endothelial Dysfunction
Kim, J., Montagnani, M., Chandrasekran, S., & Quon, M. J. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.012 · Cited by 153
Toward a broader view of mechanisms of drug cardiotoxicity
Mamoshina, P., Rodríguez, B., & Bueno‐Orovio, A. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100216 · Cited by 153
Arnold, S. V., Inzucchi, S. E., Tang, F., McGuire, D. K., Mehta, S. N., Maddox, T. M., Goyal, A., Sperling, L. S., Einhorn, D., Wong, N. D., et al. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317729252 · Cited by 144
Treating Type 2 Diabetes Mellitus with Traditional Chinese and Indian Medicinal Herbs
Wang, Z. K., Wang, J., & Chan, P. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/343594 · Cited by 153
THE MEDICAL MANAGEMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA: CURRENT TREATMENT CONSIDERATIONS
Kaplan, F. S., & Disorders, R. (2011) · Cited by 145
Yang, P., Feng, J., Peng, Q., Liu, X., & Fan, Z. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9570616 · Cited by 148
Thiazolidinedione Drugs and Cardiovascular Risks
Kaul, S., Bolger, A. F., Herrington, D. M., Giugliano, R. P., & Eckel, R. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.014 · Cited by 143
Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research
Hocher, B., Reichetzeder, C., & Alter, M. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000339028 · Cited by 145
The metabolic syndrome in hypertension: European society of hypertension position statement
Redón, J., Cífková, R., Laurent, S., Nilsson, P. M., Narkiewicz, K., Erdine, S. E., & Mancia, G. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328302ca38 · Cited by 143
Kuda, O., Jelenik, T., Jilkova, Z., Flachs, P., Rossmeisl, M., Hensler, M., Kazdova, L., Ogston, N., Baranowski, M., Gorski, J., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1305-z · Cited by 142
Metabolic Syndrome: Definition and Therapeutic Implications
Prasad, H., Ryan, D. A., Celzo, M. F., & Stapleton, D. D. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2514 · Cited by 142
Batzias, K., Antonopoulos, A. S., Oikonomou, E. K., Siasos, G., Bletsa, E., Stampouloglou, P. K., Mistakidi, C. V., Noutsou, M., Katsiki, N., Karopoulos, P., et al. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1232583 · Cited by 142
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 143
Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation
Standl, E., & Schnell, O. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441524 · Cited by 141
Tsang, R., Colley, L., & Lynd, L. D. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.08.005 · Cited by 142
Peroxisome proliferator-activated receptors, Metabolic Syndrome and Cardiovascular Disease
Azhar, S. (2010) · Future Cardiology · doi:10.2217/fca.10.86 · Cited by 146
Mitochondria as a therapeutic target for cardiac ischemia‑reperfusion injury (Review)
Marin, W., Marin, D., Ao, X., & Liu, Y. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4823 · Cited by 140
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Novel therapies with precision mechanisms for type 2 diabetes mellitus
Perreault, L., Skyler, J. S., & Rosenstock, J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00489-y · Cited by 145
Visceral Adipose Tissue Inflammation Accelerates Atherosclerosis in Apolipoprotein E–Deficient Mice
Öhman, M. K., Shen, Y., Obimba, C. I., Wright, A. P., Warnock, M., Lawrence, D. A., & Eitzman, D. T. (2008) · Circulation · doi:10.1161/circulationaha.107.717595 · Cited by 141
Inflammatory Concepts of Obesity
Rocha, V. Z., & Folco, E. J. E. (2011) · International Journal of Inflammation · doi:10.4061/2011/529061 · Cited by 140
Why we need easy access to all data from all clinical trials and how to accomplish it
Gøtzsche, P. C. (2011) · Trials · doi:10.1186/1745-6215-12-249 · Cited by 137
Lu, X., Murphy, T. C., Nanes, M. S., & Hart, C. M. (2010) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00090.2010 · Cited by 138
Green, J. B., Bethel, M. A., Paul, S. K., Ring, A., Kaufman, K. D., Shapiro, D. R., Califf, R. M., & Holman, R. R. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.09.003 · Cited by 136
Gan, L., Chitturi, S., & Farrell, G. C. (2011) · Current Gerontology and Geriatrics Research · doi:10.1155/2011/831536 · Cited by 135
Systems Pharmacology of Adverse Event Mitigation by Drug Combinations
Zhao, S., Nishimura, T., Chen, Y., Azeloglu, E. U., Gottesman, O., Giannarelli, C., Zafar, M. U., Bénard, L., Badimón, J. J., Hajjar, R. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006548 · Cited by 135
García‐Ropero, Á., Badimón, J. J., & Santos‐Gallego, C. G. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1551877 · Cited by 150
Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans
Wu, L., Xia, M., Duan, Y., Zhang, L., Jiang, H., Hu, X., Yan, H., Zhang, Y., Gu, Y., Shi, H., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1706-y · Cited by 139
Pantalone, K. M., Hobbs, T. M., Wells, B. J., Kong, S. X., Kattan, M. W., Bouchard, J. R., Yu, C., Sakurada, B., Milinovich, A., Weng, W., et al. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000093 · Cited by 137
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
Aubert, R. E., Herrera, V., Chen, W., Haffner, S. M., & Pendergrass, M. L. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01225.x · Cited by 135
Optimizing the therapeutic benefits of exercise in Type 2 diabetes
Praet, S., & van Loon, L. J. C. (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00566.2007 · Cited by 137
Targeting metabolic disorders by natural products
Tabatabaei‐Malazy, O., Larijani, B. A., & Abdollahi, M. R. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0184-8 · Cited by 136
Bain, S., Druyts, E., Balijepalli, C., Baxter, C. A., Currie, C. J., Das, R., Donnelly, R., Khunti, K., Langerman, H., Leigh, P., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12821 · Cited by 134
de Jong, M., van der Worp, H. B., van der Graaf, Y., Visseren, F. L. J., & Westerink, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0617-4 · Cited by 137
Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system
Kim, T. (2013) · World Journal of Cardiology · doi:10.4330/wjc.v5.i6.164 · Cited by 133
Robinson, E., & Grieve, D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.003 · Cited by 132
The Metabolic Syndrome—from Insulin Resistance to Obesity and Diabetes
Gallagher, E. J., LeRoith, D., & Karnieli, E. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.001 · Cited by 129
Adiponectin as a potential biomarker of vascular disease
Mohammadi, S., Arefhosseini, S. R., Ebrahimi‐Mameghani, M., Fallah, P., & Bazi, Z. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s48753 · Cited by 129
McIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Ahuja, T. K., Welton, N. J., & Dahl, M. (2011) · Europe PMC (PubMed Central) · Cited by 129
Metadata
- Authors
- Nissen, S. E., & Wolski, K.
- Affiliations
- Cleveland Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2457-2471
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127125241
- Semantic Scholar
- 238422dc26dc6a78cb2b03fad835d7d1f1f95edb
- Cited by
- 4,675
- References
- 29
- Citations by year
- 2026: 62 · 2025: 66 · 2024: 89 · 2023: 117 · 2022: 132 · 2021: 169 · 2020: 175 · 2019: 198 · 2018: 213 · 2017: 222 · 2016: 234 · 2015: 218 · 2014: 259 · 2013: 271 · 2012: 295
- FWCI
- 395.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- New England Journal of Medicine (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- rosiglitazone, myocardial infarction, cardiovascular mortality, type 2 diabetes, thiazolidinediones, drug safety, HbA1c
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Middle Aged, Myocardial Infarction, Odds Ratio, Randomized Controlled Trials as Topic, Risk Assessment, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
